Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Long-Term Remissions after First-Line Autologous Stem Cell Transplantation for Mantle Cell Lymphoma

Colin Stewart, Carolyn Owen, Neil Chua, Anthea Peters, Mona Shafey, Douglas A. Stewart, Robert Puckrin

Blood (2023) 142 (Supplement 1): 3599.

https://doi.org/10.1182/blood-2023-178097

Published: 2023

Journal Articles

Quality of Life in Patients with Chronic Lymphocytic Leukemia Initiating Venetoclax in Routine Clinical Practice across Canada: Results from the Devote Study

Andrew Aw, Versha Banerji, Sarah-Jane Bull, Pierre-André Fournier, Anthea Peters, Carolyn Owen

Blood (2022) 140 (Supplement 1): 12425–12426.

https://doi.org/10.1182/blood-2022-156749

Published: 2022

Journal Articles

Management of Canadian Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the Real-World

Anthea Peters, Grzegorz S. Nowakowski, Rosy Dabas, Theresa Amoloja, Zhenyi Xue, Caroline Koch, Eva E. Waltl, Isabelle Fleury

Blood (2022) 140 (Supplement 1): 3811–3813.

https://doi.org/10.1182/blood-2022-158550

Published: 2022

Journal Articles

Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood (2021) 138 (Supplement 1): 183.

https://doi.org/10.1182/blood-2021-148302

Published: 2021

Journal Articles

Tumor Lysis Syndrome: Incidence, Mitigation and Management in Patients with Chronic Lymphocytic Leukemia Initiating Venetoclax in Routine Clinical Practice (DEVOTE) across Canada

Versha Banerji, Nizar Abdel-Samad, Andrew Aw, Sarah-Jane Bull, Pierre-André Fournier, Nathalie Johnson, Nicole B. Laferriere, Paola Lembo, Christina H Pelizon, Anthea Peters, Carolyn Owen

Blood (2021) 138 (Supplement 1): 3744.

https://doi.org/10.1182/blood-2021-146001

Published: 2021

Journal Articles

Lack of Effectiveness of Intravenous High-Dose Methotrexate for Prevention of CNS Relapse in Patients with High-Risk DLBCL: A Retrospective Analysis from Alberta, Canada

Robert Puckrin, MD, Haidar El Darsa, MD, Sunita Ghosh, PhD P Stat, Anthea Peters, MSc, MD FRCPC, Douglas A. Stewart, MD FRCPC

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-139025

Published: 2020

Journal Articles

Epidemiology of Post-Transplant Lymphoproliferative Disorders in Children with Solid Organ Transplant over 34 Years of a Single Center Experience

Marta Rojas Vasquez, MD FRCPC, Anthea Peters, MSc, MD FRCPC, Raymond Lai, MD PhD FRCP, Curtis Mabilangan, MSc, Burton Catherine, MD FRCPC, Jutta Preiksaitis, MDFRCPC

Blood (2019) 134 (Supplement_1): 1602.

https://doi.org/10.1182/blood-2019-125344

Published: 2019

Journal Articles

Autologous Transplantation Improves Survival Rates for Follicular Lymphoma Patients Who Relapse within 2-Years of Chemoimmunotherapy: A Multi-Centre Retrospective Analysis of Consecutively Treated Patients in the Real World

Mita Manna, MD FRCPC, Richard Lee-Ying, MD FRCPC, Gwynivere Davies, MDFRCPC, Anthea Peters, MSc, MD FRCPC, Danielle Oh, MD, Colin Stewart, Douglas A. Stewart

Blood (2017) 130 (Supplement 1): 3298.

https://doi.org/10.1182/blood.V130.Suppl_1.3298.3298

Published: 2017

Journal Articles

A Phase II Clinical Trial of the Pan PI3K Inhibitor, Buparlisib, for the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia: Canadian Cancer Trials Group IND.216

Sarit Assouline, MD, Lilian Amrein, PhD, Versha Banerji, MD FRCP, Stephen Caplan, MD, Carolyn Jane Owen, MD FRCPC, Wanda Hasegawa, MD, Sue Robinson, MD, Sudeep Shavikumar, MD, Anca Prica, MD FRCP(C), Anthea Peters, MSc, MD FRCPC, Linda Hagerman, Laura Rodriguez, Tanya Skamene, MD, Lawrence Panasci, MD, Bingshu E. Chen, Annette E Hay

Blood (2017) 130 (Supplement 1): 4319.

https://doi.org/10.1182/blood.V130.Suppl_1.4319.4319

Published: 2017

Journal Articles

Significant Adverse Consequences of Initial Watchful Waiting for Follicular Lymphoma Patients: A Retrospective Analysis of Patients Diagnosed in Alberta from 1994-2011

Gwynivere Davies, MDFRCPC, Sunita Ghosh, PhD P Stat, Danielle Oh, MD, Mita Manna, MD FRCPC, Anthea Peters, MSc, MD FRCPC, Colin Stewart, Douglas A. Stewart

Blood (2017) 130 (Supplement 1): 4041.

https://doi.org/10.1182/blood.V130.Suppl_1.4041.4041

Published: 2017

Journal Articles

Monomorphic Post Transplant Lymphoproliferative Disorder (Diffuse Large B Cell Lymphoma subtype) Successfully Treated without Chemotherapy after Solid Organ Transplant in Children

Marta Rojas Vasquez, MD FRCPC, Sunil J. Desai, MRCP, FRCPC, BM, BCh, Anthea Peters, MSc, MD FRCPC, Simon Urschel, MDFAKJ, Jason Yap, MDFRCPC, Raymond Lai, PhD MD, Catherine Morgan, MDFRCPC, Jutta Preiksaitis, MDFRCPC

Blood (2017) 130 (Supplement 1): 1579.

https://doi.org/10.1182/blood.V130.Suppl_1.1579.1579

Published: 2017

Journal Articles

The FLAG Chemotherapy Regimen Is an Alternative to Anthracycline Based Therapy for the Treatment of Acute Myeloid Leukemia for Patients with Multiple Co-Morbidities or Preexisting Cardiac Disease

Lalit Saini, MD, Robert Turner, MD, Loree Larratt, MD, Joseph Brandwein, MD, Marlene Ann Hamilton, MD, Anthea Peters, MD MSc, FRCPC, Cynthia M. Wu, MD FRCPC, Nancy Zhu, MD, Jeffery M. Patterson, MD, Lauren Bolster, MD, Michael Mant, MD, Bruce Ritchie, MD, Elena Liew, MD, Imran Mirza, MD FRCPC, Graeme R. Quest, MDMSc, Sunita Gosh, PhD, P.Stat., P.Stat, Irwindeep Sandhu, MD FRCPC

Blood (2014) 124 (21): 961.

https://doi.org/10.1182/blood.V124.21.961.961

Published: 2014

Journal Articles

Autologous Stem Cell Transplantation Improves Survival for Patients with Follicular Lymphoma in First or Second Relapse: Results of a Comparative Effectiveness Instrumental Variable Analysis

Danielle H. Oh, MB ChB, Qiuli Duan, MSc, Anthea Peters, MD MSc, FRCPC, Neil Chua, MD FRCPC, Douglas A. Stewart, MD FRCPC

Blood (2014) 124 (21): 3972.

https://doi.org/10.1182/blood.V124.21.3972.3972

Published: 2014

Journal Articles

Bone Marrow Aspirates Alone without a Trephine Biopsy May be Insufficient for the Detection of Residual Leukemia Following Intensive Chemotherapy for the Treatment of Acute Myeloid Leukemia

Lalit Saini, MD, Robert Turner, MD, Loree Larratt, MD, Joseph Brandwein, MD, Marlene Ann Hamilton, MD, Anthea Peters, MD MSc, FRCPC, Cynthia M Wu, MD FRCPC, Nancy Zhu, MD, Jeffery M. Patterson, MD, Lauren Bolster, MD, Michael Mant, MD, Bruce Ritchie, MD, Elena Liew, MD, Imran Mirza, MD FRCPC, Graeme R. Quest, MDMSc, Susan Nahirniak, Sunita Gosh, PhD, P.Stat., P.Stat, Irwindeep Sandhu, MD FRCPC

Blood (2014) 124 (21): 2336.

https://doi.org/10.1182/blood.V124.21.2336.2336

Published: 2014

Journal Articles

Lymphopenia and EBER-Negativity Predict Poor Survival in Patients with Post-Transplant Lymphoproliferative Disorder (PTLD) Treated in the Rituximab Era

Anthea Peters, MD, MSc, FRCPC, Carolyn J Owen, MD, FRCPC, Karen Doucette, MD, FRCPC, Jutta Preiksaitis, MD, FRCPC

Blood (2011) 118 (21): 1645.

https://doi.org/10.1182/blood.V118.21.1645.1645

Published: 2011

Journal Articles

Autologous Stem Cell Transplantation Is a Curative Treatment Modality for Relapsed or Refractory Follicular Lymphoma, and Both Recent Rituximab Exposure and Follicular Lymphoma International Prognostic Index (FLIPI) 0–1 Scores Predict Improved Outcome

Anthea Peters, MD, MSc, FRCPC, James A Russell, MD, Andrew Daly, MD, FRCPC, Nizar J Bahlis, MD, Michelle Geddes, MD, Peter Duggan, MD, FRCPC, Mary Lynn Savoie, MD, FRCPC, Douglas A. Stewart, MD, FRCP

Blood (2010) 116 (21): 687.

https://doi.org/10.1182/blood.V116.21.687.687

Published: 2010

NARROW

Long-Term Remissions after First-Line Autologous Stem Cell Transplantation for Mantle Cell Lymphoma

Quality of Life in Patients with Chronic Lymphocytic Leukemia Initiating Venetoclax in Routine Clinical Practice across Canada: Results from the Devote Study

Management of Canadian Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the Real-World

Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Tumor Lysis Syndrome: Incidence, Mitigation and Management in Patients with Chronic Lymphocytic Leukemia Initiating Venetoclax in Routine Clinical Practice (DEVOTE) across Canada

Lack of Effectiveness of Intravenous High-Dose Methotrexate for Prevention of CNS Relapse in Patients with High-Risk DLBCL: A Retrospective Analysis from Alberta, Canada

Epidemiology of Post-Transplant Lymphoproliferative Disorders in Children with Solid Organ Transplant over 34 Years of a Single Center Experience

Autologous Transplantation Improves Survival Rates for Follicular Lymphoma Patients Who Relapse within 2-Years of Chemoimmunotherapy: A Multi-Centre Retrospective Analysis of Consecutively Treated Patients in the Real World

A Phase II Clinical Trial of the Pan PI3K Inhibitor, Buparlisib, for the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia: Canadian Cancer Trials Group IND.216

Significant Adverse Consequences of Initial Watchful Waiting for Follicular Lymphoma Patients: A Retrospective Analysis of Patients Diagnosed in Alberta from 1994-2011

Monomorphic Post Transplant Lymphoproliferative Disorder (Diffuse Large B Cell Lymphoma subtype) Successfully Treated without Chemotherapy after Solid Organ Transplant in Children

The FLAG Chemotherapy Regimen Is an Alternative to Anthracycline Based Therapy for the Treatment of Acute Myeloid Leukemia for Patients with Multiple Co-Morbidities or Preexisting Cardiac Disease

Autologous Stem Cell Transplantation Improves Survival for Patients with Follicular Lymphoma in First or Second Relapse: Results of a Comparative Effectiveness Instrumental Variable Analysis

Bone Marrow Aspirates Alone without a Trephine Biopsy May be Insufficient for the Detection of Residual Leukemia Following Intensive Chemotherapy for the Treatment of Acute Myeloid Leukemia

Lymphopenia and EBER-Negativity Predict Poor Survival in Patients with Post-Transplant Lymphoproliferative Disorder (PTLD) Treated in the Rituximab Era

Autologous Stem Cell Transplantation Is a Curative Treatment Modality for Relapsed or Refractory Follicular Lymphoma, and Both Recent Rituximab Exposure and Follicular Lymphoma International Prognostic Index (FLIPI) 0–1 Scores Predict Improved Outcome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only